

Carbiotix starts evaluation project with global laboratory testing company

Carbiotix (publ) ("Carbiotix" or "Company") today announces that the Company has started an evaluation project with a top 5 global laboratory testing company present in over 40 countries and with annual sales exceeding 3 billion Euros. The purpose of the evaluation project will be to assess how Carbiotix LinkGut gut health testing service can be rolled out globally with improvements to cost, reliability and flexibility, while exposing CarbiAXOS and the Company's Smart Prebiotic concept to leading food & beverage, nutraceutical and pharmaceutical companies.

Kristofer Cook, CEO of Carbiotix, comments

"I am very pleased to communicate that we will be starting an evaluation project with a top 5 global laboratory testing company, providing testing services to leading food & beverage, nutraceutical and pharmaceutical companies around the world. This company is present in over 40 countries, with over 25,000 employees and sales exceeding 3 billion Euros. The purpose of the evaluation project, to be carried out during 2022, will be to assess how Carbiotix LinkGut gut health testing service can be rolled out globally with improvements to cost, reliability and flexibility, while exposing CarbiAXOS and the Company's Smart Prebiotic concept to leading food & beverage, nutraceutical and pharmaceutical companies.

Our current laboratory in Sweden was always intended to be both a service and research & development lab for our testing services, prebiotic ingredients, and medical food and pharmaceutical co-interventions. This lab has allowed us to develop LinkGut, a white-label and API based B2B gut health testing service that is the lowest cost, most reliable and flexible service globally. We are however always interested in finding ways to further lower costs, and improve reliability and flexibility, while promoting our Smart Prebiotic concept to the global market. This evaluation project and the partner in question satisfies this ambition, with very clear benefits for both parties if successful.

Carbiotix will potentially be able to offer a better testing service and reduce investment requirements to expand this service globally through outsourcing. Additionally, we will be able to quickly ramp up CarbiAXOS sales activities by exposing Carbiotix Smart Prebiotic modulators to leading food & beverage, nutraceutical and pharmaceutical companies through our partner's network. The logic is quite simple, the more companies who utilise Carbiotix Smart Prebiotics, the more consumers will test their gut health and thus create more business for our testing partner. This clear synergy would be a win-win for both companies as the opportunity to sell, validate and personalise gut health interventions, especially prebiotics, enters an exponential growth phase. I see this potential partnership as a very interesting and key channel to market, especially as we prepare for the upcoming market launch of CarbiAXOS for nutraceutical applications in the US."

This is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the Company's contact person set out below on 19 January 2022.

Forward-looking statements

This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated



Press Release
19 January 2022

with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.

For further information:

Carbiotix AB
Kristofer Cook, CEO
Tel: +46 (0)70-879 65 80
E-mail: kristofer.cook@carbiotix.com

Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a portfolio of microbiome modulators covering prebiotic ingredients, medical foods, and therapeutics, along with cost-effective gut health testing services.